198 related articles for article (PubMed ID: 9014759)
1. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line.
Johnston PG; Geoffrey F; Drake J; Voeller D; Grem JL; Allegra CJ
Eur J Cancer; 1996 Nov; 32A(12):2148-54. PubMed ID: 9014759
[TBL] [Abstract][Full Text] [Related]
2. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line.
Esaki T; Nakano S; Tatsumoto T; Kuroki-Migita M; Mitsugi K; Nakamura M; Niho Y
Cancer Res; 1992 Dec; 52(23):6501-6. PubMed ID: 1423296
[TBL] [Abstract][Full Text] [Related]
3. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
Kim R; Tanabe K; Inoue H; Toge T
Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
[TBL] [Abstract][Full Text] [Related]
4. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves.
Nishiyama M; Yamamoto W; Park JS; Okamoto R; Hanaoka H; Takano H; Saito N; Matsukawa M; Shirasaka T; Kurihara M
Clin Cancer Res; 1999 Sep; 5(9):2620-8. PubMed ID: 10499641
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
6. In-vitro effect of a combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) on human gastric cancer cell lines: timing of cisplatin treatment.
Cho H; Imada T; Oshima T; Shiozawa M; Rino Y; Takanashi Y
Gastric Cancer; 2002; 5(1):43-6. PubMed ID: 12021859
[TBL] [Abstract][Full Text] [Related]
7. Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line.
Chu E; Zinn S; Boarman D; Allegra CJ
Cancer Res; 1990 Sep; 50(18):5834-40. PubMed ID: 1697502
[TBL] [Abstract][Full Text] [Related]
8. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
Mans DR; Grivicich I; Peters GJ; Schwartsmann G
Eur J Cancer; 1999 Dec; 35(13):1851-61. PubMed ID: 10674003
[TBL] [Abstract][Full Text] [Related]
9. Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.
Chen TL; Erlichman C
Cancer Chemother Pharmacol; 1992; 30(5):370-6. PubMed ID: 1380407
[TBL] [Abstract][Full Text] [Related]
10. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis.
Perez EA; Hack FM; Webber LM; Chou TC
Cancer Chemother Pharmacol; 1993; 33(3):245-50. PubMed ID: 8269606
[TBL] [Abstract][Full Text] [Related]
11. Effect of consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo.
Araki H; Fukushima M; Kamiyama Y; Shirasaka T
Cancer Lett; 2000 Nov; 160(2):185-91. PubMed ID: 11053648
[TBL] [Abstract][Full Text] [Related]
12. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
Ren Q; Van Groeningen CJ; Hardcastle A; Aherne GW; Geoffroy F; Allegra CJ; Johnston PG; Grem JL
Oncol Res; 1997; 9(2):77-88. PubMed ID: 9167189
[TBL] [Abstract][Full Text] [Related]
13. [Mechanism for synergistic antitumor effect in the combination of 5-fluorouracil with cisplatin in vivo tumor models: from the view of biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Ohshimo H; Kimura A; Fukushima M
Gan To Kagaku Ryoho; 1991 Mar; 18(3):403-9. PubMed ID: 2003740
[TBL] [Abstract][Full Text] [Related]
14. Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP.
Zhan M; Liu X
Chin Med J (Engl); 1999 Apr; 112(4):336-9. PubMed ID: 11593534
[TBL] [Abstract][Full Text] [Related]
15. [Fundamental study of combination chemotherapy with THP, 5-FU and CDDP for human KB carcinoma cell line and its multidrug resistant cell line KB-C1--usefulness of treatment with 5-FU preceding CDDP].
Kishimoto H; Manno Y; Tanaka H; Moridera K; Urade M
Gan To Kagaku Ryoho; 2001 Apr; 28(4):505-9. PubMed ID: 11329785
[TBL] [Abstract][Full Text] [Related]
16. Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
Yang D; Qu J; Qu X; Cao Y; Xu L; Hou K; Feng W; Liu Y
Cancer Chemother Pharmacol; 2015 Sep; 76(3):575-86. PubMed ID: 26208739
[TBL] [Abstract][Full Text] [Related]
17. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo.
Shirasaka T; Shimamoto Y; Ohshimo H; Saito H; Fukushima M
Cancer Chemother Pharmacol; 1993; 32(3):167-72. PubMed ID: 8500219
[TBL] [Abstract][Full Text] [Related]
18. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma.
Chu E; Koeller DM; Johnston PG; Zinn S; Allegra CJ
Mol Pharmacol; 1993 Apr; 43(4):527-33. PubMed ID: 8474431
[TBL] [Abstract][Full Text] [Related]
19. Synergistic induction of ICAM-1 expression by cisplatin and 5-fluorouracil in a cancer cell line via a NF-kappaB independent pathway.
Takizawa K; Kamijo R; Ito D; Hatori M; Sumitani K; Nagumo M
Br J Cancer; 1999 Jun; 80(7):954-63. PubMed ID: 10362102
[TBL] [Abstract][Full Text] [Related]
20. In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.
Guglielmi A; Aschele C; Mori A; Baldo C; Russo P; Debernardis D; Valenti M; Bruno S; Taverna M; Rosso R
Clin Cancer Res; 1995 Nov; 1(11):1337-44. PubMed ID: 9815929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
